Mendelian neurodevelopmental disorder
MONDO:0100500A neurodevelopmental disorder that is caused by genetic modifications where those modifications are inherited from a parent's genome.
208 clinical trials for this condition and its sub-types, 0 tagged with Mendelian neurodevelopmental disorder itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Mendelian neurodevelopmental disorder
-
Genetic developmental and epileptic encephalopathy 2 trials · 83 incl. sub-types
105 sub-types
- Dravet syndrome 39 trials
- Lennox-Gastaut syndrome 26 trials · 27 incl. sub-types Sub-types →
- Developmental and epileptic encephalopathy, 2 10 trials
- Developmental and epileptic encephalopathy, 4 6 trials
- Neonatal-onset developmental and epileptic encephalopathy 0 trials · 5 incl. sub-types Sub-types →
- Developmental and epileptic encephalopathy, 11 4 trials
- Developmental and epileptic encephalopathy, 14 3 trials
- Developmental and epileptic encephalopathy, 1 2 trials
- Developmental and epileptic encephalopathy, 17 2 trials
- Developmental and epileptic encephalopathy 114 1 trial
- Developmental and epileptic encephalopathy, 35 1 trial
- Developmental and epileptic encephalopathy, 7 1 trial
- Non-neonatal early infantile epileptic encephalopathy 1 trial
- DNM1-encephalopathy and neurodevelopmental disorder 0 trials Sub-types →
- TMEM63B-related developmental and epileptic encephalopathy with anemia 0 trials
- Developmental and epileptic encephalopathy 100 0 trials
- Developmental and epileptic encephalopathy 101 0 trials
- Developmental and epileptic encephalopathy 102 0 trials
- Developmental and epileptic encephalopathy 103 0 trials
- Developmental and epileptic encephalopathy 104 0 trials
- Developmental and epileptic encephalopathy 105 with hypopituitarism 0 trials
- Developmental and epileptic encephalopathy 106 0 trials
- Developmental and epileptic encephalopathy 107 0 trials
- Developmental and epileptic encephalopathy 108 0 trials
- Developmental and epileptic encephalopathy 109 0 trials
- Developmental and epileptic encephalopathy 110 0 trials
- Developmental and epileptic encephalopathy 111 0 trials
- Developmental and epileptic encephalopathy 112 0 trials
- Developmental and epileptic encephalopathy 113 0 trials
- Developmental and epileptic encephalopathy 115 0 trials
- Developmental and epileptic encephalopathy 116 0 trials
- Developmental and epileptic encephalopathy 118 0 trials
- Developmental and epileptic encephalopathy 119 0 trials
- Developmental and epileptic encephalopathy 120 0 trials
- Developmental and epileptic encephalopathy 121 0 trials
- Developmental and epileptic encephalopathy 6B 0 trials
- Developmental and epileptic encephalopathy 89 0 trials
- Developmental and epileptic encephalopathy 91 0 trials
- Developmental and epileptic encephalopathy 92 0 trials
- Developmental and epileptic encephalopathy 93 0 trials
- Developmental and epileptic encephalopathy 96 0 trials
- Developmental and epileptic encephalopathy 97 0 trials
- Developmental and epileptic encephalopathy 98 0 trials
- Developmental and epileptic encephalopathy 99 0 trials
- Developmental and epileptic encephalopathy, 15 0 trials
- Developmental and epileptic encephalopathy, 18 0 trials
- Developmental and epileptic encephalopathy, 19 0 trials
- Developmental and epileptic encephalopathy, 23 0 trials
- Developmental and epileptic encephalopathy, 27 0 trials
- Developmental and epileptic encephalopathy, 3 0 trials
- Developmental and epileptic encephalopathy, 30 0 trials
- Developmental and epileptic encephalopathy, 36 0 trials
- Developmental and epileptic encephalopathy, 37 0 trials
- Developmental and epileptic encephalopathy, 38 0 trials
- Developmental and epileptic encephalopathy, 40 0 trials
- Developmental and epileptic encephalopathy, 48 0 trials
- Developmental and epileptic encephalopathy, 49 0 trials
- Developmental and epileptic encephalopathy, 5 0 trials
- Developmental and epileptic encephalopathy, 50 0 trials
- Developmental and epileptic encephalopathy, 51 0 trials
- Developmental and epileptic encephalopathy, 52 0 trials
- Developmental and epileptic encephalopathy, 53 0 trials
- Developmental and epileptic encephalopathy, 54 0 trials
- Developmental and epileptic encephalopathy, 55 0 trials
- Developmental and epileptic encephalopathy, 56 0 trials
- Developmental and epileptic encephalopathy, 57 0 trials
- Developmental and epileptic encephalopathy, 58 0 trials
- Developmental and epileptic encephalopathy, 59 0 trials
- Developmental and epileptic encephalopathy, 60 0 trials
- Developmental and epileptic encephalopathy, 61 0 trials
- Developmental and epileptic encephalopathy, 62 0 trials
- Developmental and epileptic encephalopathy, 63 0 trials
- Developmental and epileptic encephalopathy, 64 0 trials
- Developmental and epileptic encephalopathy, 65 0 trials
- Developmental and epileptic encephalopathy, 66 0 trials
- Developmental and epileptic encephalopathy, 67 0 trials
- Developmental and epileptic encephalopathy, 68 0 trials
- Developmental and epileptic encephalopathy, 69 0 trials
- Developmental and epileptic encephalopathy, 6A 0 trials
- Developmental and epileptic encephalopathy, 70 0 trials
- Developmental and epileptic encephalopathy, 71 0 trials
- Developmental and epileptic encephalopathy, 72 0 trials
- Developmental and epileptic encephalopathy, 73 0 trials
- Developmental and epileptic encephalopathy, 74 0 trials
- Developmental and epileptic encephalopathy, 75 0 trials
- Developmental and epileptic encephalopathy, 76 0 trials
- Developmental and epileptic encephalopathy, 77 0 trials
- Developmental and epileptic encephalopathy, 78 0 trials
- Developmental and epileptic encephalopathy, 79 0 trials
- Developmental and epileptic encephalopathy, 8 0 trials
- Developmental and epileptic encephalopathy, 80 0 trials
- Developmental and epileptic encephalopathy, 81 0 trials
- Developmental and epileptic encephalopathy, 82 0 trials
- Developmental and epileptic encephalopathy, 83 0 trials
- Developmental and epileptic encephalopathy, 84 0 trials
- Developmental and epileptic encephalopathy, 85, with or without midline brain defects 0 trials
- Developmental and epileptic encephalopathy, 86 0 trials
- Developmental and epileptic encephalopathy, 87 0 trials
- Developmental and epileptic encephalopathy, 88 0 trials
- Developmental and epileptic encephalopathy, 9 0 trials
- Developmental and epileptic encephalopathy, 90 0 trials
- Hemiplegic migraine-developmental and epileptic encephalopathy spectrum 0 trials
- Microcephaly, seizures, and developmental delay 0 trials
- Multiple congenital anomalies-hypotonia-seizures syndrome 2 0 trials
- Neonatal-onset encephalopathy with rigidity and seizures 0 trials
-
Prader-Willi syndrome 32 trials
5 sub-types
-
Rett syndrome 31 trials
-
Intellectual disability, autosomal dominant 0 trials · 23 incl. sub-types
29 sub-types
- Autosomal dominant syndromic intellectual disability 0 trials · 15 incl. sub-types Sub-types →
- Autosomal dominant non-syndromic intellectual disability 0 trials · 8 incl. sub-types Sub-types →
- Intellectual disability, autosomal dominant 5 2 trials
- Intellectual developmental disorder, autosomal dominant 64 0 trials
- Intellectual developmental disorder, autosomal dominant 65 0 trials
- Intellectual developmental disorder, autosomal dominant 66 0 trials
- Intellectual developmental disorder, autosomal dominant 67 0 trials
- Intellectual developmental disorder, autosomal dominant 68 0 trials
- Intellectual developmental disorder, autosomal dominant 69 0 trials
- Intellectual developmental disorder, autosomal dominant 70 0 trials
- Intellectual developmental disorder, autosomal dominant 71, with behavioral abnormalities 0 trials
- Intellectual developmental disorder, autosomal dominant 72 0 trials
- Intellectual developmental disorder, autosomal dominant 74 0 trials
- Intellectual developmental disorder, autosomal dominant 75 0 trials
- Intellectual developmental disorder, autosomal dominant 76 0 trials
- Intellectual disability, autosomal dominant 1 0 trials
- Intellectual disability, autosomal dominant 10 0 trials
- Intellectual disability, autosomal dominant 11 0 trials
- Intellectual disability, autosomal dominant 2 0 trials
- Intellectual disability, autosomal dominant 24 0 trials
- Intellectual disability, autosomal dominant 3 0 trials
- Intellectual disability, autosomal dominant 38 0 trials
- Intellectual disability, autosomal dominant 39 0 trials
- Intellectual disability, autosomal dominant 4 0 trials
- Intellectual disability, autosomal dominant 40 0 trials
- Intellectual disability, autosomal dominant 42 0 trials
- Intellectual disability, autosomal dominant 6 0 trials
- Intellectual disability, autosomal dominant 9 0 trials
- Neurodevelopmental disorder with or without hyperkinetic movements and seizures, autosomal dominant 0 trials
-
X-linked intellectual disability 1 trial · 15 incl. sub-types
2 sub-types
- X-linked syndromic intellectual disability 0 trials · 12 incl. sub-types Sub-types →
- Non-syndromic X-linked intellectual disability 0 trials · 3 incl. sub-types Sub-types →
-
CACNA1A-related complex neurodevelopmental disorder 1 trial · 9 incl. sub-types
4 sub-types
- Spinocerebellar ataxia type 6 9 trials
- Developmental and epileptic encephalopathy, 42 1 trial
- Episodic ataxia type 2 1 trial
- Migraine, familial hemiplegic, 1 1 trial
-
Autosomal recessive primary microcephaly 0 trials · 8 incl. sub-types
29 sub-types
- Microcephaly with or without short stature 0 trials · 8 incl. sub-types Sub-types →
- Microcephalic primordial dwarfism due to ZNF335 deficiency 0 trials
- Microcephaly 1, primary, autosomal recessive 0 trials
- Microcephaly 11, primary, autosomal recessive 0 trials
- Microcephaly 12, primary, autosomal recessive 0 trials
- Microcephaly 13, primary, autosomal recessive 0 trials
- Microcephaly 14, primary, autosomal recessive 0 trials
- Microcephaly 15, primary, autosomal recessive 0 trials
- Microcephaly 16, primary, autosomal recessive 0 trials
- Microcephaly 17, primary, autosomal recessive 0 trials
- Microcephaly 19, primary, autosomal recessive 0 trials
- Microcephaly 2, primary, autosomal recessive, with or without cortical malformations 0 trials
- Microcephaly 20, primary, autosomal recessive 0 trials
- Microcephaly 21, primary, autosomal recessive 0 trials
- Microcephaly 22, primary, autosomal recessive 0 trials
- Microcephaly 23, primary, autosomal recessive 0 trials
- Microcephaly 24, primary, autosomal recessive 0 trials
- Microcephaly 25, primary, autosomal recessive 0 trials
- Microcephaly 28, primary, autosomal recessive 0 trials
- Microcephaly 29, primary, autosomal recessive 0 trials
- Microcephaly 3, primary, autosomal recessive 0 trials
- Microcephaly 30, primary, autosomal recessive 0 trials
- Microcephaly 31, primary, autosomal recessive 0 trials
- Microcephaly 4, primary, autosomal recessive 0 trials
- Microcephaly 5, primary, autosomal recessive 0 trials
- Microcephaly 7, primary, autosomal recessive 0 trials
- Microcephaly 8, primary, autosomal recessive 0 trials
- Microcephaly 9, primary, autosomal recessive 0 trials
- Microcephaly with simplified gyral pattern 0 trials
-
Smith-Magenis syndrome 5 trials
-
Rubinstein-Taybi syndrome 3 trials
3 sub-types
-
Alternating hemiplegia of childhood 3 trials
3 sub-types
-
FOXG1 disorder 2 trials
-
Orofaciodigital syndrome I 1 trial
-
Dyneinopathy 0 trials · 1 incl. sub-types
2 sub-types
-
Intellectual disability, autosomal recessive 0 trials · 1 incl. sub-types
3 sub-types
-
Alzahrani-Kuwahara syndrome 0 trials
-
Amish lethal microcephaly 0 trials
-
Au-Kline syndrome 0 trials
-
CK syndrome 0 trials
-
2 sub-types
-
Delpire-McNeill syndrome 0 trials
-
1 sub-type
-
Harel-Yoon syndrome 0 trials
-
Houge-Janssens syndrome 3 0 trials
-
KCNH1 associated disorder 0 trials
2 sub-types
- Temple-Baraitser syndrome 0 trials
- Zimmermann-Laband syndrome 1 0 trials
-
Li-Takada-Miyake syndrome 0 trials
-
Pitt-Hopkins-like syndrome 2 0 trials
-
Popov-Chang syndrome 0 trials
-
Stankiewicz-Isidor syndrome 0 trials
-
Wieacker-Wolff syndrome 0 trials
-
2 sub-types
-
3 sub-types
-
Microcephaly and chorioretinopathy 0 trials
3 sub-types
- Microcephaly and chorioretinopathy 1 0 trials
- Microcephaly and chorioretinopathy 2 0 trials
- Microcephaly and chorioretinopathy 3 0 trials
-
2 sub-types
- NDE1-related microhydranencephaly 0 trials
- Lissencephaly 4 0 trials
-
1 sub-type
-
Squalene synthase deficiency 0 trials
Most studied deeper sub-types
-
New hope for infants with severe epilepsy: fenfluramine trial launches
Disease control CompletedThis phase 3 trial is testing the safety and tolerability of fenfluramine (Fintepla) in 25 infants aged 1 to 2 years with Dravet syndrome, a severe form of epilepsy. The drug is given as an oral solution twice daily alongside other seizure medications. Researchers will monitor he…
Phase 3 • Sponsor: UCB BIOSCIENCES, Inc. • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Can a new drug curb seizures in children with severe epilepsy?
Disease control CompletedResearchers are testing an experimental drug called TAK-935 in children aged 2 to 17 with Dravet syndrome or Lennox-Gastaut syndrome, two severe forms of epilepsy that often resist treatment. The trial compares TAK-935 added to standard anti-seizure medications against a placebo …
Phase 2 • Sponsor: Takeda • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Can a pill tame the relentless hunger of Prader-Willi syndrome?
Disease control CompletedThis phase 2 trial tests an oral drug called ARD-101 in adults with Prader-Willi syndrome, a genetic condition that causes an unrelenting feeling of hunger. Researchers give the drug twice daily for 28 days to see if it safely reduces hyperphagia, the intense drive to eat, using …
Phase 2 • Sponsor: Aardvark Therapeutics, Inc. • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Can a new Add-On drug tame seizures in dravet syndrome?
Disease control CompletedThis phase 3 trial tests whether soticlestat, an experimental oral drug, can reduce convulsive seizures in children and young adults with Dravet syndrome, a severe form of epilepsy. Participants continue their standard antiseizure therapy and also receive either soticlestat or a …
Phase 3 • Sponsor: Takeda • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Can a High-Fat diet and therapy tame seizures in rare childhood epilepsy?
Disease control CompletedThis study asks whether adding a medically supervised ketogenic diet to occupational therapy can help children aged 4 to 7 with ARX gene mutations and drug-resistant epilepsy. Twenty children will take part: half follow the ketogenic diet while the other half do not, and both gro…
Sponsor: Uskudar University • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Can a common drug boost brain function in kids with rare genetic disorder?
Disease control CompletedThis phase 2 trial tested sodium valproate, a drug used for seizures, in 41 children with Rubinstein-Taybi syndrome (RTS), a rare genetic condition causing intellectual disability. Participants aged 6 to 21 received either the drug or a placebo for one year. Researchers measured …
Phase 2 • Sponsor: University Hospital, Bordeaux • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
MCT8 deficiency drug withdrawal trial raises questions about lifelong treatment
Disease control CompletedThis phase 3 study looked at what happens when males with MCT8 deficiency (a rare genetic condition affecting thyroid hormone transport) stop taking tiratricol. Twenty participants who had been stable on tiratricol were randomly assigned to either continue the drug or receive a p…
Phase 3 • Sponsor: Rare Thyroid Therapeutics International AB • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Could a common mineral ease rare genetic disorder? zinc trial shows promise
Disease control CompletedThis pilot trial tested whether taking oral zinc every day for 6 months is safe and doable for people with GNAO1 disorders, a rare genetic condition that causes movement problems, seizures, and developmental delays. 13 participants aged 6 months to 30 years took zinc acetate. The…
Phase 2 • Sponsor: Children's University Hospital Cologne, Germany • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Growth hormone trial aims to boost muscle in Prader-Willi patients
Disease control CompletedThis completed Phase 3 study tested somatropin, a synthetic growth hormone, in 33 Japanese children and adults with Prader-Willi syndrome. The goal was to see if it safely improves body composition by increasing lean body mass and reducing fat. Participants were divided into thre…
Phase 3 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
Special oil may curb paralytic attacks in rare childhood disease
Disease control CompletedThis pilot study tested whether triheptanoin oil, a special fat taken by mouth, can reduce the number of sudden paralytic attacks in children with Alternating Hemiplegia of Childhood (AHC), a rare genetic disorder. Ten participants aged 15 and older with confirmed ATP1A3 mutation…
Phase 2 • Sponsor: Institut National de la Santé Et de la Recherche Médicale, France • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New epilepsy drug shows promise in long-term safety trial
Disease control CompletedThis study tested the long-term safety of a drug called LP352 (bexicaserin) in 41 people aged 12 to 65 with severe epilepsy syndromes like Dravet or Lennox-Gastaut. Participants took the drug three times daily for up to 52 weeks. The main goal was to check for side effects, while…
Phase 2 • Sponsor: Longboard Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New hope for rare seizure patients: Long-Term drug safety confirmed
Disease control CompletedThis study looked at the long-term safety of a drug called fenfluramine (ZX008) for people with rare seizure disorders like Dravet syndrome and Lennox-Gastaut syndrome. A total of 412 participants who had completed earlier studies took the drug and were monitored for side effects…
Phase 3 • Sponsor: Zogenix, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
Hope for ataxia: experimental drug shows promise in Late-Stage trial
Disease control CompletedThis study tested a drug called troriluzole in 141 adults with spinocerebellar ataxia, a rare disease that affects balance and coordination. Participants took either the drug or a placebo daily for 8 weeks. The main goal was to see if troriluzole could improve symptoms like walki…
Phase 2/3 • Sponsor: Biohaven Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
New lifestyle program aims to help Prader-Willi patients keep weight off
Disease control CompletedThis completed trial tested a personalized program of physical activity, nutrition guidance, and education for 128 adults with Prader-Willi syndrome. Participants followed the program during a 5-week hospital stay, with the goal of stabilizing or reducing their body mass index (B…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
Can a daily tablet quiet the seizures of two devastating genetic disorders?
Symptom relief CompletedResearchers are testing an experimental drug called soticlestat in people with two rare genetic conditions: Dup15q syndrome and CDKL5 deficiency disorder. Both conditions cause frequent motor seizures that are hard to control. The trial enrolls about 20 participants who take one …
Phase 2 • Sponsor: Takeda • Aim: Symptom relief
Last updated Sep 12, 2026 00:00 UTC
-
Can an experimental drug cut drop seizures in a severe childhood epilepsy?
Symptom relief CompletedResearchers are testing whether soticlestat, an experimental drug, can reduce major drop seizures when added to standard antiseizure therapy in children, teenagers, and adults with Lennox-Gastaut syndrome. About 270 participants will take either soticlestat or a placebo for 16 we…
Phase 3 • Sponsor: Takeda • Aim: Symptom relief
Last updated Sep 12, 2026 00:00 UTC
-
Low-THC cannabis extract tested against rett syndrome symptoms
Symptom relief CompletedResearchers are testing a full-spectrum medicinal cannabis extract called NTI164 in girls and young women with Rett syndrome, a rare genetic disorder that affects movement, speech, and behavior. The study includes 14 participants aged 5 to 20 who take the extract daily for 16 wee…
Phase 1/2 • Sponsor: Fenix Innovation Group • Aim: Symptom relief
Last updated Sep 11, 2026 00:00 UTC
-
Could a web course tame insomnia for home ventilator users?
Symptom relief CompletedThis study tests whether a web-based training program helps people with COPD who use a noninvasive ventilator (NIV) at home stick to their therapy and sleep better. Participants receive online lessons on using the device, and researchers measure their compliance and insomnia seve…
Sponsor: KTO Karatay University • Aim: Symptom relief
Last updated Sep 04, 2026 00:00 UTC
-
Can playful therapy unlock new skills in children with intellectual disability?
Symptom relief CompletedThis trial tests whether adding DIR/Floortime™—a play-based, relationship-focused therapy—to standard care can improve emotional development and everyday skills in children aged 4-12 with mild to moderate intellectual developmental disorder. Over 10 weeks, some children receive t…
Sponsor: GIFT University • Aim: Symptom relief
Last updated Aug 15, 2026 00:00 UTC
-
Virtual therapy helps kids with rare epilepsy gain daily living skills
Symptom relief CompletedThis study tested whether remote occupational therapy could help children and teens (ages 7-18) with Dravet syndrome improve their daily living skills and satisfaction. 14 families participated in online sessions where a therapist coached the child or parent. The goal was to see …
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Symptom relief
Last updated Jun 27, 2026 12:34 UTC
-
Could a ketamine drug ease rett syndrome?
Symptom relief CompletedThis early study tested esketamine, a form of ketamine, in 3 girls with Rett syndrome. The goal was to see if weekly infusions over five weeks could improve symptoms and be safe. The trial is complete, but with only 3 participants, it's too small to draw firm conclusions.
Early phase 1 • Sponsor: Children's Hospital of Fudan University • Aim: Symptom relief
Last updated Jun 27, 2026 12:33 UTC
-
Can a wakefulness drug beat daytime sleepiness in Prader-Willi syndrome?
Symptom relief CompletedThis phase 2 study tested whether pitolisant, a drug that promotes wakefulness, can safely reduce excessive daytime sleepiness in people with Prader-Willi syndrome. The trial enrolled 65 participants aged 6 to 65 and compared pitolisant to a placebo over 11 weeks, followed by an …
Phase 2 • Sponsor: Harmony Biosciences Management, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 12:31 UTC
-
Warm baths tested as seizure treatment for rare childhood disorder
Symptom relief CompletedThis study tested whether daily 20-minute warm baths could safely reduce seizures in 8 children (ages 6 months to 6 years) with CDKL5 deficiency, a rare genetic disorder causing hard-to-control seizures. The treatment was added to their usual medications for 12 weeks. The goal wa…
Sponsor: Xuanwu Hospital, Beijing • Aim: Symptom relief
Last updated Jun 27, 2026 12:08 UTC
-
Could a simple oxygen mask halt rare childhood paralysis attacks?
Symptom relief CompletedThis study tested whether breathing high-flow oxygen for 15 minutes can stop dystonic or plegic attacks in children with Alternating Hemiplegia of Childhood (AHC), a rare genetic disorder causing temporary paralysis and muscle spasms. 24 participants used oxygen or a placebo (med…
Phase 2 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Symptom relief
Last updated Jun 27, 2026 12:06 UTC
-
Can a 'Love Hormone' spray tame Prader-Willi symptoms?
Symptom relief CompletedThis study tested whether oxytocin nasal spray, sometimes called the 'love hormone,' can improve behavior and eating problems in adults with Prader-Willi syndrome. Fifty participants received either oxytocin or a placebo daily or every three days for 28 days. Researchers measured…
Phase 2/3 • Sponsor: University Hospital, Toulouse • Aim: Symptom relief
Last updated Jun 27, 2026 08:02 UTC
-
Would families trade daily growth hormone shots for weekly ones?
Knowledge-focused CompletedChildren with growth hormone deficiency often need daily injections, which can be hard to keep up with. Researchers in Belgium and Luxembourg are asking families in the BELGROW registry to fill out a questionnaire about whether they would consider switching to long-acting growth …
Sponsor: Cliniques universitaires Saint-Luc- Université Catholique de Louvain • Aim: Knowledge-focused
Last updated Sep 21, 2026 23:00 UTC
-
Rare disease mystery: NIH launches deep dive into Smith-Magenis syndrome
Knowledge-focused CompletedThis study follows nearly 600 people with Smith-Magenis syndrome (SMS), a rare genetic condition, to track how their health, behavior, and development change over time. Researchers will perform detailed medical exams, genetic tests, and surveys to better understand the syndrome's…
Sponsor: National Human Genome Research Institute (NHGRI) • Aim: Knowledge-focused
Last updated Sep 11, 2026 00:00 UTC
-
Hunting for the first clues of a devastating brain disease
Knowledge-focused CompletedThis study follows people who have a 50% chance of inheriting a gene for spinocerebellar ataxia, a group of progressive brain disorders that affect movement and coordination. The goal is to identify the earliest clinical signs and biological markers that appear before the disease…
Sponsor: Institut National de la Santé Et de la Recherche Médicale, France • Aim: Knowledge-focused
Last updated Aug 21, 2026 00:00 UTC
-
How many people live with rare epilepsies in spain? a nationwide count aims to find out
Knowledge-focused CompletedThis study looks at medical records from public hospitals in Spain to count how many children, teenagers, and adults have Dravet syndrome or Lennox-Gastaut syndrome, and how many new cases are diagnosed each year. It is an observational study, meaning no treatment or intervention…
Sponsor: Takeda • Aim: Knowledge-focused
Last updated Aug 20, 2026 00:00 UTC
-
Personalized sleep apnea treatment on the horizon?
Knowledge-focused CompletedThis study investigates why people develop obstructive sleep apnea (OSA) and whether the underlying cause affects how they respond to different treatments. Researchers will test three approaches—CPAP, a sleep medication (eszopiclone), and supplemental oxygen—in adults with OSA. T…
Phase 2 • Sponsor: University of California, San Diego • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Walking analysis sheds light on rare genetic disorders
Knowledge-focused CompletedThis study looked at whether a special walking test (3D gait analysis) can help identify movement problems in people with rare genetic diseases like Tuberous Sclerosis and STXBP1. About 40 participants aged 6 and older who could walk without help took part. The goal was to see if…
Sponsor: Universiteit Antwerpen • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:31 UTC
-
Fever's impact on seizures in rare genetic disorder revealed
Knowledge-focused CompletedThis study looked at how fever changes seizure patterns in people with CDKL5 deficiency disorder, a rare genetic condition that causes hard-to-control seizures. Researchers surveyed parents of 131 affected individuals to collect information on fever history and seizure frequency.…
Sponsor: Xuanwu Hospital, Beijing • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:08 UTC
-
Researchers map the features of a rare genetic syndrome
Knowledge-focused CompletedThis study looked at 15 people with a rare genetic condition called DDX3X syndrome, which can cause intellectual disability and sometimes autism. Researchers used interviews, play-based assessments, and genetic tests to better understand the condition. The goal was to describe th…
Sponsor: Icahn School of Medicine at Mount Sinai • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:05 UTC
-
Rett syndrome bone mystery: study probes early osteoporosis
Knowledge-focused CompletedThis study looked at why girls with Rett syndrome often develop weak bones (osteoporosis) at a very young age. Researchers checked bone density, looked at medical history, and measured certain proteins in the blood. The goal was to find risk factors and understand the biological …
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:05 UTC
-
Hormone study aims to unlock Prader-Willi feeding mystery
Knowledge-focused CompletedThis completed study looked at how appetite-regulating hormones change in infants with Prader-Willi syndrome during the first four years of life. Researchers collected blood samples from 215 infants to understand why they switch from poor feeding to severe overeating and obesity.…
Sponsor: University Hospital, Toulouse • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:05 UTC
-
Could a single DNA test solve the mystery of rare brain diseases in kids?
Knowledge-focused CompletedThis study looked at whether whole genome sequencing (a complete read of a person's DNA) can help diagnose leukodystrophies, a group of rare brain diseases that are hard to identify. Researchers enrolled 236 children with white matter abnormalities on brain scans but no known gen…
Sponsor: Children's Hospital of Philadelphia • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:56 UTC
-
Rare genetic Disorder's mental health patterns explored
Knowledge-focused CompletedThis study looked at 25 people with FOXP1 syndrome, a rare genetic condition, to better understand their psychiatric symptoms. Researchers used interviews and questionnaires with families to assess hyperactivity, attention, anxiety, autism traits, and more. The goal is to improve…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 26, 2026 19:02 UTC
-
Liquid vs. pill: new study tests easier way to take seizure drug
Knowledge-focused CompletedThis study tested two versions of the seizure medication stiripentol (Diacomit®) in 24 healthy adults: a capsule and a liquid suspension. The goal was to see if the liquid form is absorbed by the body in a similar way to the capsule. If so, it could provide a more convenient opti…
Phase 1 • Sponsor: Biocodex • Aim: Knowledge-focused
Last updated Jun 26, 2026 18:16 UTC
-
New study tracks why some women have lasting pain after C-Section
Knowledge-focused CompletedThis completed study followed 477 women in Denmark who had a planned cesarean delivery. Researchers used text-message surveys to track pain levels, medication use, and how pain affected daily life over several months. The goal was to better understand how common persistent pain i…
Sponsor: Nordsjaellands Hospital • Aim: Knowledge-focused
Last updated Jun 26, 2026 12:36 UTC